Mark Leonard Singleton Sells 4,000 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 4,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $4.75, for a total value of $19,000.00. Following the transaction, the chief financial officer now owns 34,665 shares in the company, valued at approximately $164,658.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Friday, March 22nd, Mark Leonard Singleton sold 5,541 shares of Bioventus stock. The stock was sold at an average price of $5.39, for a total value of $29,865.99.

Bioventus Trading Up 0.2 %

Shares of BVS stock opened at $4.64 on Wednesday. The stock’s fifty day moving average price is $4.96 and its two-hundred day moving average price is $4.48. The company has a market cap of $367.35 million, a PE ratio of -1.84 and a beta of 0.50. Bioventus Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $6.08. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.01 and a current ratio of 1.53.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $135.42 million for the quarter, compared to the consensus estimate of $124.84 million. Bioventus had a positive return on equity of 2.25% and a negative net margin of 30.49%. Equities analysts predict that Bioventus Inc. will post 0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Large investors have recently modified their holdings of the business. LPL Financial LLC acquired a new stake in shares of Bioventus in the 4th quarter valued at $26,000. PNC Financial Services Group Inc. boosted its holdings in shares of Bioventus by 1,845.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company’s stock valued at $30,000 after acquiring an additional 2,030 shares in the last quarter. UBS Group AG boosted its holdings in shares of Bioventus by 72.9% during the 4th quarter. UBS Group AG now owns 12,744 shares of the company’s stock valued at $33,000 after acquiring an additional 5,372 shares in the last quarter. Delphia USA Inc. acquired a new stake in shares of Bioventus during the 4th quarter valued at $33,000. Finally, XTX Topco Ltd acquired a new stake in shares of Bioventus during the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum increased their price target on Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.